Eli Lilly and Company $LLY Position Raised by Physicians Financial Services Inc.

Physicians Financial Services Inc. grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 21.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,970 shares of the company’s stock after acquiring an additional 872 shares during the quarter. Eli Lilly and Company comprises about 1.3% of Physicians Financial Services Inc.’s investment portfolio, making the stock its 24th largest holding. Physicians Financial Services Inc.’s holdings in Eli Lilly and Company were worth $4,571,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of LLY. Brady Martz Wealth Solutions LLC increased its holdings in shares of Eli Lilly and Company by 21.0% in the 1st quarter. Brady Martz Wealth Solutions LLC now owns 1,368 shares of the company’s stock worth $1,258,000 after acquiring an additional 237 shares during the period. Aspen Investment Management Inc boosted its stake in Eli Lilly and Company by 3.0% during the 1st quarter. Aspen Investment Management Inc now owns 3,249 shares of the company’s stock valued at $2,988,000 after purchasing an additional 94 shares during the period. Old North State Trust LLC boosted its stake in Eli Lilly and Company by 0.4% during the 4th quarter. Old North State Trust LLC now owns 7,414 shares of the company’s stock valued at $7,968,000 after purchasing an additional 27 shares during the period. J. Derek Lewis & Associates Inc. bought a new position in Eli Lilly and Company in the 4th quarter worth about $1,196,000. Finally, Purpose Unlimited Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $193,000. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.0%

Shares of NYSE:LLY opened at $1,098.78 on Monday. The company has a 50 day moving average of $1,016.10 and a 200-day moving average of $1,017.13. The firm has a market cap of $1.03 trillion, a P/E ratio of 39.03, a P/E/G ratio of 1.20 and a beta of 0.53. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,182.73. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period last year, the firm posted $3.34 earnings per share. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th were given a dividend of $1.73 per share. The ex-dividend date was Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a report on Friday, May 22nd. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 8th. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. Wolfe Research reaffirmed an “outperform” rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Finally, HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price target for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,227.74.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s latest quarter showed standout fundamentals, with revenue up 55.5% year over year to $19.80 billion and full-year guidance raised to $82 billion-$85 billion, reinforcing the company’s leadership in GLP-1 drugs like Mounjaro. Prediction: Eli Lilly Will Trade at $1,200 on This Date
• Positive Sentiment: Analysts and market commentators remain bullish, citing Lilly’s rapid earnings growth, heavy manufacturing investment, and ongoing leadership in obesity and diabetes treatments as reasons the stock could keep climbing. Under Dave Ricks, Lilly Is Minting Money on GLP-1 Drugs and Spending It Wisely
• Positive Sentiment: New collaborations around Lilly TuneLab, including partnerships with Charles River and Chai Discovery, expand the company’s AI-driven drug discovery ecosystem and could support longer-term pipeline productivity. Chai Discovery Collaborates with Lilly TuneLab to Offer AI Capabilities to Select Biotechs
• Neutral Sentiment: Several articles highlighted ongoing pipeline progress, including completion of trials for retatrutide and mevidalen, which are worth watching but did not include definitive late-stage results. Retatrutide Trial Completion Signals Next Step for Eli Lilly’s Diabetes Pipeline
• Neutral Sentiment: Some commentary framed Lilly as still undervalued relative to its growth narrative and pointed to AI-driven healthcare as another possible upside theme, but these pieces were largely opinion-based rather than new company-specific catalysts. Eli Lilly (LLY) Stock Could Be 24.7% Undervalued on Its Growth Narrative
• Negative Sentiment: LLY also saw a short-term pullback in the prior session, showing that even with strong fundamentals, investors have been taking some profits after the stock’s big run. Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: A report that Lilly has begun denying some 340B discounts could create friction with healthcare buyers and adds a potential reimbursement-related overhang. Eli Lilly begins denying 340B discounts

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.